0001062993-24-010182.txt : 20240514 0001062993-24-010182.hdr.sgml : 20240514 20240514163312 ACCESSION NUMBER: 0001062993-24-010182 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240510 FILED AS OF DATE: 20240514 DATE AS OF CHANGE: 20240514 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: MANIAN BALA S CENTRAL INDEX KEY: 0000941871 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38624 FILM NUMBER: 24945005 MAIL ADDRESS: STREET 1: 1025 TERRA BELLA AVE CITY: MOUNTAIN VIEW STATE: CA ZIP: 94043 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: VACCINEX, INC. CENTRAL INDEX KEY: 0001205922 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 161603202 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1895 MOUNT HOPE AVE CITY: ROCHESTER STATE: NY ZIP: 14620 BUSINESS PHONE: 585-271-2700 MAIL ADDRESS: STREET 1: 1895 MOUNT HOPE AVE CITY: ROCHESTER STATE: NY ZIP: 14620 FORMER COMPANY: FORMER CONFORMED NAME: VACCINEX INC DATE OF NAME CHANGE: 20021114 4 1 form4.xml STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES X0508 4 2024-05-10 0001205922 VACCINEX, INC. VCNX 0000941871 MANIAN BALA S C/O VACCINEX, INC. 1895 MOUNT HOPE AVENUE ROCHESTER NY 14620 1 0 0 0 0 Stock Option (Right to Buy) 1633.8 2020-05-15 Common Stock 36 36 D Stock Option (Right to Buy) 829.5 2021-05-14 Common Stock 74 74 D Stock Option (Right to Buy) 451.5 2022-05-11 Common Stock 136 136 D Stock Option (Right to Buy) 235.2 2023-05-12 Common Stock 253 253 D Stock Option (Right to Buy) 86.1 2024-05-11 Common Stock 684 684 D Stock Option (Right to Buy) 5.75 2024-05-10 4 A 0 2685 3.96 A 2024-05-10 2034-05-10 Common Stock 2685 2685 D Stock Option (Right to Buy) 5.75 2024-05-10 4 A 0 10108 0 A 2025-05-10 Common Stock 10108 10108 D This option expires on May 14, 2029 or five years following retirement or cessation of services, whichever occurs first. This option expires on May 12, 2030 or five years following retirement or cessation of services, whichever occurs first. This option expires on May 9, 2031 or five years following retirement or cessation of services, whichever occurs first. This option expires on May 9, 2032 or five years following retirement or cessation of services, whichever occurs first. This option expires on May 8, 2033 or five years following retirement or cessation of services, whichever occurs first. Pursuant to the Issuer's Director Compensation Plan, in a transaction exempt under Rule 16b-3, the reporting person elected to receive these options in lieu of $10,625 for retainer and meeting fees during the first quarter of 2024. The number of options was calculated in accordance with the Black-Scholes valuation model and all such options are immediately exercisable. This option was granted pursuant to the Company's 2018 Omnibus Incentive Plan in a transaction exempt under Rule 16b-3 and expires on May 10, 2034 or five years following retirement or cessation of services, whichever occurs first. All figures in this Form 4 reflect the Issuer's 1-for-15 reverse stock split effected on September 25, 2023 and 1-for-14 reverse stock split effected on February 19, 2024. /s/ Maurice Zauderer, Attorney-in-Fact for Bala S. Manian 2024-05-14